Connect with us

Hi, what are you looking for?


This biopharma stock more than doubled on Monday: find out more

Shares of Imago Biosciences Inc (NASDAQ: IMGO) opened more than 100% up this morning after Merck & Co Inc (NYSE: MRK) said it will acquire the biopharmaceutical firm in a $1.35 billion deal.

Imago Biosciences shareholders to get a 105% premium

The all-cash agreement translates to $36 a share – just over double the price at which the stock closed on Friday.

Merck expects the transaction to help boost its haematology portfolio. In the press release, Robert M. Davis – the President and Chief Executive of Merck & Co said:

We continue to invest in our pipeline with a focus on applying our unique capabilities to unlock the value of breakthrough science. This acquisition of Imago augments our pipeline and strengthen our presence in the growing field of Haematology.

The pharmaceutical behemoth expects the deal to close in the first quarter of 2023. Merck shares are also in the green on Monday.

Imago Biosciences also reported Q3 results this month

Imago Biosciences is a California-based company that’s committed to developing treatments for bone marrow diseases, including Myeloproliferative Neoplasms (MPNs). According to Dr Hugh Y. Reinhoff – its Founder and Chief Executive:

This agreement leverages Merck’s industry-leading clinical development expertise to maximise the therapeutical potential off bomedemstat while providing important value for our shareholders.

The stock market news arrives about two weeks after Imago Biosciences reported its third-quarter financial results. The Nasdaq-listed firm debuted last year at roughly $16 a share.

Centerview Partners and Latham & Watkins are acting as Imago Biosciences’ financial and legal advisors, respectively, for this deal.

The post This biopharma stock more than doubled on Monday: find out more appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like


    Inflation appears to be on the decline. The Personal Consumption Expenditures Price Index (PCEPI), which is the Federal Reserve’s preferred measure of inflation, grew...


    Solana (SOL/USD) is enormously underrated as a cryptocurrency project, even with its hiccups – including the latest exploit on one of the ecosystem apps....

    Editor's Pick

    The new eSIM infrastructure will help modernise the IoT connectivity market with fast, secure connections and reduced vendor lock-in. 1oT, a tech startup from...


    The latest Job Openings and Labor Turnover Survey from the Bureau of Labor Statistics shows the total number of job openings in the economy...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023